Skip to main content
SpringerLink
Log in

Medikamente zur Behandlung bipolarer Störungen

  • Chapter
  • First Online:
Kompendium der Psychiatrischen Pharmakotherapie

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Stimmungsstabilisierer im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Ein Schwerpunkt liegt in der Darstellung des Risikos der Antidepressiva bei der Verordnung bei der bipolaren Depression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Amsterdam JD, Lorenzo-Luaces L, Soeller I et al (2015) Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study. J Affect Disord 185:31–37

    Article  CAS  Google Scholar 

  • Berk M, Daglas R, Dandash O et al (2017) Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial. Br J Psychiatry 210(6):413–421

    Article  Google Scholar 

  • Berk M, Turner A, Malhi G et al (2019) A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med 17(1):18

    Article  Google Scholar 

  • Chang HY, Tseng PT, Stubbs B et al (2017) The efficacy and tolerability of paliperidone in mania of bipolar disorder: a preliminary meta-analysis. Exp Clin Psychopharmacol 25(5):422–433

    Article  Google Scholar 

  • Chen TY, Kamali M, Chu CS et al (2019) Divalproex and its effect on suicide risk in bipolar disorder: a systematic review and meta-analysis of multinational observational studies. J Affect Disord 245:812–818

    Article  CAS  Google Scholar 

  • Cheniaux E, Nardi AE (2019) Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder. Expert Opin Drug Saf 18(10):893–913

    Article  CAS  Google Scholar 

  • DGBS, DGPPN (2019) S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. Langversion 2.0, Update Mai 2019. https://www.awmf.org/leitlinien/detail/ll/038-019.html

  • Geddes JR, Gardiner A, Rendell J et al (2016) Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Lancet Psychiatry 3(1):31–39

    Article  Google Scholar 

  • Grover S, Kukreti R (2014) HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics 24(2):94–112

    Article  CAS  Google Scholar 

  • Grunze H, Vieta E, Goodwin GM et al (2018) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry 19(1):2–58

    Article  Google Scholar 

  • Hiemke C, Bergemann N, Clement HW et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1-02):9–62

    CAS  PubMed  Google Scholar 

  • Hou L, Heilbronner U, Degenhardt F et al (2016) Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet 387(10023):1085–1093

    Article  CAS  Google Scholar 

  • Huang RY, Hsieh KP, Huang WW et al (2016) Use of lithium and cancer risk in patients with bipolar disorder: population-based cohort study. Br J Psychiatry 209(5):393–399

    Article  Google Scholar 

  • Joas E, Karanti A, Song J (2017) Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder. Br J Psychiatry 210(3):197–202

    Article  Google Scholar 

  • Kessing LV, Gerds TA, Feldt-Rasmussen B et al (2015) Lithium and renal and upper urinary tract tumors – results from a nationwide population-based study. Bipolar Disord 17(8):805–813

    Article  CAS  Google Scholar 

  • Kessing LV, Gerds TA, Knudsen NN et al (2017) Association of lithium in drinking water with the incidence of dementia. JAMA Psychiatry 74(10):1005–1010

    Article  Google Scholar 

  • Kessing LV, Bauer M, Nolen WA et al (2018) Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. Bipolar Disord. Online ahead of print

    Google Scholar 

  • Ketter TA, Miller S, Dell’Osso B, Wang PW (2016) Treatment of bipolar disorder: review of evidence regarding quetiapine and lithium. J Affect Disord 191:256–273

    Article  CAS  Google Scholar 

  • Lähteenvuo M, Tanskanen A, Hoti F et al (2017) Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Lancet Psychiatry 4(7):547–553

    Article  Google Scholar 

  • Lähteenvuo M, Tanskanen A, Taipale H et al (2018) Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. Jama Psychiatry 75(4):347–355

    Article  Google Scholar 

  • Lorenzo-Luaces L, Amsterdam JD, Soeller I, DeRubeis RJ (2016) Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk. Acta Psychiatr Scand 133(6):459–469

    Article  CAS  Google Scholar 

  • Melhuish Beaupre LM, Tiwari KA, Gonçalves VF et al (2020) Antidepressant-associated mania in bipolar disorder: a review and meta-analysis of potential clinical and genetic risk factors. J Clin Psychopharmacol 40(2):180–185

    Article  Google Scholar 

  • Miura T, Noma H, Furukawa TA et al (2014) Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 1(5):351–359

    Article  Google Scholar 

  • Owens DC (2019) Sodium valproate in psychiatric practice: time for a change in perception. Br J Psychiatry 13:1–3

    Google Scholar 

  • Pereira C, Chavarria V, Vian J et al (2018) Mitochondrial agents for bipolar disorder. Int J Neuropsychopharmacol 21(6):550–569

    Article  CAS  Google Scholar 

  • Rosenblat JD (2019) Targeting the immune system in the treatment of bipolar disorder. Psychopharmacology 236:2909–2921

    Article  CAS  Google Scholar 

  • Saraf G, Moazen-Zadeh E, Pinto JV et al (2020) Early intervention for people at high risk of developing bipolar disorder: a systematic review of clinical trials. Lancet Psychiatry. Online ahead of print

    Google Scholar 

  • Shine B, McKnight RF, Leaver L, Geddes JR (2015) Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 386(9992):461–468

    Article  CAS  Google Scholar 

  • Smith KA, Cipriani A (2017) Lithium and suicide in mood disorders: updated meta-review of the scientific literature. Bipolar Disord 19(7):575–586

    Article  CAS  Google Scholar 

  • Szegedi A, Durgam S, Mackle M et al (2018) Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry 175(1):71–79

    Article  Google Scholar 

  • Szmulewicz AG, Angriman F, Samamé C (2017) Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis. Acta Psychiatr Scand 135(6):527–538

    Article  CAS  Google Scholar 

  • Viktorin A, Rydén E, Thase ME et al (2017) The risk of treatment-emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry 174(4):341–348

    Article  Google Scholar 

  • Vöhringer PA, Ostacher MJ, El-Mallakh RS et al (2015) Antidepressants in type II versus type I bipolar depression: a randomized discontinuation trial. J Clin Psychopharmacol 35(5):605–508

    Article  Google Scholar 

  • Yatham LN, Kennedy SH, Parikh SV et al (2018) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20(2):97–170

    Article  Google Scholar 

  • Young RC, Mulsant BH, Sajatovic M et al (2017) GERI-BD: a randomized double-blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry 174(11):1086–1093

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mannheim, Deutschland

    PD Dr. med. Michael Paulzen & Prof. Dr. med. Gerhard Gründer

  2. Mainz, Deutschland

    Otto Benkert

Authors
  1. PD Dr. med. Michael Paulzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gerhard Gründer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Otto Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Benkert .

Editor information

Editors and Affiliations

  1. ehemals Universitäts-Klinikum Mainz, Mainz, Germany

    Otto Benkert

  2. Klinik für Psychiatrie und Psychotherapie, ehemals Universitäts-Klinikum München Campus Innenstadt, München, Germany

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Paulzen, M., Gründer, G., Benkert, O. (2021). Medikamente zur Behandlung bipolarer Störungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-61753-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-61753-3_2

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-61752-6

  • Online ISBN: 978-3-662-61753-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation